Singapore's S*BIO Adds $26M for Phase II Studies in Cancer

Hollingsworth, Catherine
October 2008
BioWorld Today;10/21/2008, Vol. 19 Issue 205, p1
The article reports that S*BIO Pte. Ltd. has raised $26 million to fund phase II trials for the SB939 and SB1518 cancer drugs in 2008. The financing was led by Bio*One Capital, a member of the Singapore Economic Development Authority and Aravis Venture. In a statement, chief executive Jan Anders Karlsson said that they are looking forward to test their lead compounds in other international trial sites and advance them to Phase II development.


Related Articles

  • S BIO initiates US Phase I trials of cancer drug.  // PharmaWatch: Cancer;Nov2008, Vol. 7 Issue 11, p7 

    The article reports on the initiation of S Bio company for the Phase I clinical trials of SB1518, an inhibitor in patients with leukemia and certain types of lymphoma. It states the trials for SB4518 comprise of ascending dose studies. According to Jan-Anders Karlsson, chief executive officer...

  • European Haematology Association.  // BioWorld Today;6/15/2010, Vol. 21 Issue 114, p4 

    The article reports on the Phase I/II dose escalation trial of S*BIO Pte. Ltd.'s oral JAK2 inhibitor SB1518 which drew positive safety, tolerability and pharmacokinetic/pharmacodynamic findings.

  • S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR BIOAMARKER.  // Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p7 

    The article focuses on the two-year research partnership forged by S*BIO Pte Ltd. with the National University Hospital-National University of Singapore Tissue Repository (NUH-NUS TR). The partnership is aimed at conducting biomarker research and at evaluating the responsiveness of tumors to the...

  • S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p1 

    The article reports that the clinical trial of the novel anti-cancer drug was initiated by the S*BIO Pte Ltd. in Singapore. The SB939 is a histone deacetylase (HDAC) inhibitor which is a targeted anti-cancer therapeutics. The SB939 Phase I trial was conducted to determine its pharmacokinetic and...

  • CLINIC ROUNDUP.  // BioWorld Today;9/19/2008, Vol. 19 Issue 183, p7 

    This section offers news briefs on the pharmaceutical industry. Avigen Inc. has completed the double-blind portion of its Phase IIb trial for AV650 used in the treatment of spasticity linked to multiple sclerosis. Positive results were reported by Incyte Corp. from Phase IIa trials of topical...

  • Correction.  // BioWorld Today;4/6/2007, Vol. 18 Issue 67, p2 

    A correction to the misidentification of the location of the headquarters of the company S*BIO Pte. Ltd. that was published in the April 4, 2007 issue is presented.

  • S*BIO Adds $26M for Phase II Cancer Studies.  // Bioworld Week;10/27/2008, Vol. 16 Issue 43, p3 

    The article reports on the $26 million funds raised by S☆BIO Pte. Ltd. in 2008. The company raised $26 million in a Series B financing round, which will be used mainly to move its lead compound for cancer, SB939 and SB1518, into Phase II trials. SB939, currently in Phase I testing in both...

  • Phase II funding for venom peptides. Desjardins, Lisa // Chemistry in Australia;Mar2012, Vol. 79 Issue 2, p8 

    The article reports on the completion of the financing for the phase 2 clinical trial of the lead compound Xen2174 from Xenome.

  • S*BIO ADVANCES JAK2 INHIBITOR SB1518 INTO PHASE 1/2 TRIAL.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p4 

    The article reports on the initiation of a Phase ½ clinical trial of JAK2-selective kinase inhibitor drug SB1518 in patients with chronic idiopathic myelofibrosis (CIMF) in Australia in January 2009. The trial, launched by Singaporean company S*BIO Pte Ltd., will be conducted in two phases....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics